{"id":"https://openalex.org/W4308400002","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0811","title":"811 PD1 and LAG3 synergize on CD8+ T cells to hinder IFN\u03b3-dependent anti-tumor immunity","display_name":"811 PD1 and LAG3 synergize on CD8+ T cells to hinder IFN\u03b3-dependent anti-tumor immunity","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4308400002","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0811"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2022-sitc2022.0811","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0811","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0811","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A847.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A847.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078884068","display_name":"Lawrence Peter Andrews","orcid":"https://orcid.org/0000-0002-4923-142X","observed_orcids":["https://orcid.org/0000-0002-4923-142X"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lawrence Andrews","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075852714","display_name":"Carly Cardello","orcid":"https://orcid.org/0000-0002-2810-7681","observed_orcids":["https://orcid.org/0000-0002-2810-7681"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carly Cardello","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039379693","display_name":"Jian Guo Cui","orcid":"https://orcid.org/0000-0002-4015-9484","observed_orcids":["https://orcid.org/0000-0002-4015-9484"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jian Cui","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008106149","display_name":"Creg J. Workman","orcid":"https://orcid.org/0000-0002-9964-9509","observed_orcids":["https://orcid.org/0000-0002-9964-9509"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Creg Workman","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001000053","display_name":"Dario A.A. Vignali","orcid":"https://orcid.org/0000-0002-2771-5992","observed_orcids":["https://orcid.org/0000-0002-2771-5992"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dario Vignali","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I170201317"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I170201317"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A847","last_page":"A847"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.9449999928474426},{"id":"https://openalex.org/keywords/lag-3","display_name":"LAG-3","score":0.9419999718666077},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.8980000019073486},{"id":"https://openalex.org/keywords/tumor-immune-evasion","display_name":"tumor immune evasion","score":0.5289999842643738},{"id":"https://openalex.org/keywords/exhausted-t-cells","display_name":"exhausted T cells","score":0.8130000233650208},{"id":"https://openalex.org/keywords/tox-transcription-factor","display_name":"TOX transcription factor","score":0.8619999885559082},{"id":"https://openalex.org/keywords/interferon-gamma-signaling","display_name":"interferon-gamma signaling","score":0.8870000243186951},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.6859999895095825},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.7419999837875366},{"id":"https://openalex.org/keywords/relatlimab","display_name":"relatlimab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.7889999747276306},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.5270000100135803},{"id":"https://openalex.org/keywords/tim-3","display_name":"TIM-3","score":0.6620000004768372},{"id":"https://openalex.org/keywords/ifn-gamma-receptor","display_name":"IFN-gamma receptor","score":0.628000020980835}],"concepts":[{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5976995825767517},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5710495710372925},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5463623404502869},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.48699504137039185},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.48277536034584045},{"id":"https://openalex.org/C129374314","wikidata":"https://www.wikidata.org/wiki/Q909381","display_name":"Interleukin 21","level":4,"score":0.42396941781044006},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4110238552093506},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.39830613136291504},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.395523339509964},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3678455948829651},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.19133326411247253},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.05371236801147461},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2022-sitc2022.0811","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0811","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0811","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A847.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2022-sitc2022.0811","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0811","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0811","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A847.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4308400002.pdf","grobid_xml":"https://content.openalex.org/works/W4308400002.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4401420347","https://openalex.org/W3212923359","https://openalex.org/W4313373865","https://openalex.org/W4416088315","https://openalex.org/W4366221220","https://openalex.org/W4389380113","https://openalex.org/W4308399064","https://openalex.org/W4403587207","https://openalex.org/W4401420128","https://openalex.org/W4313380426"],"abstract_inverted_index":{"Background":[0],"Overcoming":[1],"immune-mediated":[2],"resistance":[3],"to":[4,48,99,113,247,269,272,300,372],"PD1":[5,44,115,235,264,352],"blockade":[6],"remains":[7],"a":[8,22,130,171,284],"challenge,":[9],"however":[10],"enhanced":[11,200,226,310,369],"efficacy":[12],"has":[13],"now":[14],"been":[15],"demonstrated":[16,231,268],"in":[17,145,161,190,201,339,364,395],"metastatic":[18],"melanoma":[19],"patients":[20],"with":[21,109,170,208,225,232,254,328,347,388,397],"combinatorial":[23],"regimen":[24],"of":[25,159,177,216,234,280,291,321,330,392],"nivolumab":[26],"and":[27,45,82,141,251,257,265,282,293,353,368],"relatlimab,":[28],"an":[29],"anti-LAG3":[30,393],"targeting":[31],"antibody":[32],"recently":[33],"FDA":[34],"approved.":[35],"Despite":[36],"this":[37,296],"success,":[38],"little":[39,165],"is":[40,58],"known":[41],"about":[42],"how":[43],"LAG3":[46,266,354],"synergize":[47,270],"hinder":[49],"anti-tumor":[50],"immunity,":[51],"particularly":[52],"on":[53,376],"CD8+":[54,100,121,179,194,205,218,242],"T":[55,68,101,122,243],"cells,":[56,196],"which":[57,197],"the":[59,73,80,110,274,278,316,324,385,389],"dominant":[60],"LAG3-expressing":[61],"intratumoral":[62],"population":[63,297],"signifying":[64],"highly":[65],"dysfunctional":[66],"exhausted":[67],"(TEX)":[69],"cells":[70,102,181,207,220,244],"regulated":[71],"by":[72,155,260,276,289,304],"transcription":[74],"factor":[75],"TOX.":[76],"Methods":[77],"To":[78],"understand":[79],"cellular":[81],"mechanistic":[83,382],"basis":[84],"for":[85,315,384],"PD1/LAG3":[86],"synergy,":[87],"conditional":[88],"knock-in":[89],"mice":[90,106,128,191,202],"\u201csurgically":[91],"dissect\u201d":[92],"Pdcd1":[93],"and/or":[94,116],"Lag3":[95],"floxed":[96],"alleles":[97],"restricted":[98],"expressing":[103],"E8ICre.GFP.":[104],"These":[105,379],"were":[107,245,267,345],"crossed":[108],"pMEL":[111,180,195,206,219,361],"transgene":[112],"assess":[114],"LAG3-sufficient":[117],"or":[118,236,238],"deficient":[119],"gp100-specific":[120],"cell":[123],"populations":[124],"adoptively":[125],"transferred":[126],"into":[127,182],"harboring":[129],"B16-gp100-overexpressing":[131],"tumor.":[132],"Single-cell":[133],"RNAseq":[134],"analysis":[135],"was":[136,152,168,185,198,229,298,313],"performed,":[137],"identifying":[138],"both":[139],"effector":[140],"IFN\u03b3-stimulated":[142],"genes":[143,337],"up-regulated":[144],"PD1/LAG3-deficient":[146,204,217,241,331,340,360],"pMEL.":[147,162,332],"The":[148],"IFN\u03b3":[149,256,311,377],"signaling":[150,312],"pathway":[151],"further":[153,199],"interrogated":[154,308],"retroviral":[156],"transduced":[157],"knockdown":[158,320],"IFN\u03b3R":[160,322,348],"Results":[163],"While":[164],"therapeutic":[166,213,223,325],"benefit":[167,326],"observed":[169,259,327],"prophylactic":[172],"adoptive":[173],"transfer":[174],"(AT;":[175],"d-1)":[176],"wild-type":[178],"mice,":[183],"there":[184],"reduced":[186,346,365],"B16-gp100":[187],"tumor":[188,366],"growth":[189,367],"receiving":[192,203],"PD1-deficient":[193],"long-term":[209],"tumor-free":[210],"survival.":[211],"Likewise,":[212],"AT":[214,233,329,362],"(d6)":[215],"showed":[221],"initial":[222],"benefit,":[224],"survival,":[227],"that":[228],"not":[230],"LAG3-deficient,":[237],"wild-type,":[239],"counterparts.":[240],"shown":[246,299],"be":[248,301],"more":[249,252,285],"proliferative":[250],"functional,":[253],"increased":[255,373],"GzmB":[258],"flow":[261],"cytometry.":[262],"Interestingly,":[263],"together":[271],"modulate":[273],"TEXprogram":[275],"restraining":[277],"expression":[279,290],"TOX":[281],"promoting":[283],"terminally-exhausted":[286],"phenotype":[287],"defined":[288],"TIM3":[292],"Ly108.":[294],"As":[295],"transcriptionally":[302],"distinct":[303],"transcriptomic":[305],"analysis,":[306],"we":[307],"whether":[309],"responsible":[314],"phenotypes":[317],"observed.":[318],"Retroviral":[319],"reversed":[323],"In":[333],"addition,":[334],"other":[335],"IFN-responsive":[336],"upregulated":[338],"pMEL,":[341],"such":[342],"as":[343,359],"CCL5,":[344],"knockdown.":[349],"Conclusions":[350],"Overall":[351],"limit":[355],"antitumor":[356],"immune":[357],"effects":[358],"resulted":[363],"survival":[370],"due":[371],"functionality,":[374],"dependent":[375],"signaling.":[378],"results":[380],"provide":[381],"insight":[383],"success":[386],"seen":[387],"clinical":[390],"development":[391],"agents":[394],"combination":[396],"anti-PD1.":[398]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2022-11-11T00:00:00"}